UNIVERSITY HEALTH NETWORK Patent applications |
Patent application number | Title | Published |
20160140300 | METHOD AND SYSTEM FOR AUTOMATED QUALITY ASSURANCE AND AUTOMATED TREATMENT PLANNING IN RADIATION THERAPY - Methods and systems for evaluating a proposed treatment plan for radiation therapy, for evaluating one or more delineated regions of interest for radiation therapy, and/or for generating a proposed treatment plan for radiation therapy. Machine learning based on historical data may be used. | 05-19-2016 |
20160128785 | SYSTEM AND METHOD FOR DECREMENT EVOKED POTENTIAL (DEEP) MAPPING TO IDENTIFY COMPONENTS OF THE ARRYTHMOGENIC CIRCUIT IN CARDIAC ARRHYTHMIAS - Various embodiments are described herein for a system and a method for identifying the arrhythmogenic circuit of a patient or subject. In one embodiment, the method comprises obtaining data for electrograms recorded at various locations of the heart while programmed ventricular pacing with extra stimuli was performed, obtaining decrement values for at least two different locations of the heart using the recorded electrograms, generating at least a portion of a decrement map using the decrement values, and identifying the arrhythmogenic circuit based on electrograms having significant decremental properties. | 05-12-2016 |
20160095944 | NOVEL MULTIMODAL CT/OPTICAL AGENTS - The present application relates to compositions comprising an iodinated contrast agent and indocyanine green co-encapsulated inside a liposomal carrier, various uses thereof as well as methods for their preparation. | 04-07-2016 |
20160085925 | APPARATUS, SYSTEM AND METHOD FOR TRACKING DRUGS DURING A REPACKAGING AND ADMINISTERING PROCESS - A system for tracking drugs during a transfer and administering process is configured to reduce labeling errors that can occur during that process. The system includes a storage container reader configured to read a set of one or more storage-container-associated machine-readable indicia positioned on a container containing a drug. The set of one or more storage-container-associated machine-readable indicia identifies the drug. The system further includes, at the point of care of a patient, an indicia-generating device configured to generate machine readable drug-delivery-container-associated indicia identifying the drug based on the storage-container-associated machine-readable indicia. A drug delivery container reader, also located at the point of care, is configured to read both sets of machine readable indicia to verify that the drug delivery container has been correctly labelled. A method implemented by the system results in the reduction in labeling errors. | 03-24-2016 |
20160061832 | Biomarkers for Inflammatory Bowel Disease with Ankylosing Spondylitis - There is provided herein a method for categorizing a patient having inflammatory bowel disease as being at risk for developing ankylosing spondylitis. The method comprises the use of a patient level of auto-antibodies directed against noggin (NOG) and/or sclerostin (SOST) to determine a risk for the patient developing ankylosing spondylitis. There is also provided methods of monitoring ankylosing spondylitis treatment using these auto-antibodies. | 03-03-2016 |
20160045114 | Method and System for Imaging and Collection of Data for Diagnostic Purposes - A system for acquiring data regarding a wound in tissue comprises at least one light source configured to directly illuminate a target surface with a homogeneous field of excitation light. An optical sensor is configured to detect signals responsive to illumination of an illuminated portion of a wound and the area around the wound. A thermal sensor is configured to detect thermal information regarding the illuminated portion of the wound and the area around the wound. A processor receives the detected signals and the detected thermal information and outputs data regarding the illuminated portion of the wound and the area around the wound. The output data may include wound size of the illuminated portion of the wound, bacterial load of the illuminated portion of the wound, or at least one temperature associated with the illuminated portion of the wound and the area around the wound. The data output by the processor may be displayed on a display of the system. | 02-18-2016 |
20150359912 | J-Aggregate Forming Nanoparticle - There is provided herein a nanovesicle having a bilayer comprising a saturated first phospholipid and no more than about 15 molar % of a second phospholipid covalently conjugated to a J-aggregate forming dye. | 12-17-2015 |
20150252006 | INHIBITORS OF PEPTIDYL ARGININE DEIMINASE (PAD) ENZYMES AND USES THEREOF - The present application relates to imidazolidinecliones, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or associated with the hypercitrullination of proteins by peptidyl arginine deiminase (PAD) enzymes. In particular, the present application includes compounds of Formula I, and compositions and uses thereof: (I). | 09-10-2015 |
20150182504 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR - Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist. | 07-02-2015 |
20150152185 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 06-04-2015 |
20150133677 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONES - The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): | 05-14-2015 |
20150117936 | CONNECTOR APPARATUS - A connector apparatus has a first portion and a second portion. The first portion mounts to an upright that has knobby hand grip protrusions. The second portion provides a connection for a laterally extending cross-member. The first portion interacts with the knobby hand grip protrusions to have a combination of a first degree of freedom permitting motion in one direction, while inhibiting motion in a second degree of freedom. The second portion has a releasable connection to the cross-member, and when engaged, has a degree of freedom of motion about an axis of the second portion cross-wise to the axis of the upright. The second portion has a releasable, retained, pin connector with a quarter-turn lock to prevent accidental disengagement. The connection of the second portion is offset such that when two connectors are seated back-to-back their cross-tie connections stand in substantially the same horizontal plane relative to the ground. | 04-30-2015 |
20150115119 | CANTILEVERED SUPPORT SYSTEM - A cantilevered support system is provided. The cantilevered support system comprises a vertical support pole and longitudinally extending upper and lower support arm assemblies that are securable to a wall. | 04-30-2015 |
20150104815 | Porphyrin-Lipid Stabilized Nanoparticles for Surface Enhanced Raman Scattering Based Imaging - Herein are provided nano-particles comprising a nanocore of Raman-scattering material stabilized by a bilayer comprising a porphyrin-phospholipid conjugate, methods of making the same and their use in Surface Enhanced Raman Scattering. | 04-16-2015 |
20150104430 | Methods and Compositions for Generating Pancreatic Progenitors and Functional Beta Cells from hPSCs - Methods and compositions for producing NKX6-1+ pancreatic progenitor cells and/or insulin producing cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least one endodermal cell into a NKX6-1+ pancreatic progenitor cell, the combination optionally further comprising at least one Noggin component. | 04-16-2015 |
20140371202 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME - The present teaching provide indazole compounds represented by Structural Formulae (I) or (I′) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells. | 12-18-2014 |
20140370039 | IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia. | 12-18-2014 |
20140322808 | POPULATIONS OF HEMATOPOIETIC PROGENITORS AND METHODS OF ENRICHING STEM CELLS THEREFOR - There is described herein a method of enriching a population of stem cells for hematopoietic progenitors. The method comprises inducing hematopoietic differentiation in a population of human embryonic stem cells or human induced pluripotent stem cells; sorting the population based on expression of CD43 and at least one of CD34, CD31 and CD144; and selecting a fraction that is at least one of CD34 | 10-30-2014 |
20140306495 | PATIENT CARRIER - A patient carrier comprises a patient support configured to be locatable above a toileting receptacle. The patient support includes a back support portion, a leg support portion, and a seat support portion. The patient support is movable about a first axis between an upright orientation and an inclined orientation. The seat support portion is movable about a second axis relative to the back support portion and leg support portion, and is operable to transition between a seating configuration and a toileting configuration when the patient support is in the inclined orientation. | 10-16-2014 |
20140296845 | COIL ELECTRODE FOR THERMAL THERAPY - A coil electrode for use with an RFA (radio frequency ablation) apparatus, has a lead portion, and a helical portion coupled to the lead portion, the helical portion being formed of Nitinol SE510. Further, an RFA (radio frequency ablation) apparatus, comprises an applicator, the applicator including a handle and a cannulating delivery needle mounted to the handle, the cannulating delivery needle including a tip spaced apart from the handle. A coil electrode includes a lead portion housed in the cannulating delivery needle, and a helical portion coupled to the lead portion, the helical portion formed of Nitinol. The helical portion has a retracted state when housed within the cannulating delivery needle and a deployed state when moved out of the tip of the cannulating delivery needle. | 10-02-2014 |
20140277309 | FUNCTIONAL ELECTRICAL STIMULATION METHOD, USE AND APPARATUS FOR MOOD ALTERATION - A method and apparatus for providing functional electrical stimulation to an individual for altering a mood or emotional parameter associated with a mood or emotional state is provided. The method involves providing functional electrical stimulation to facial muscles of the individual so as to elicit a detectable contraction in said muscles associated with a facial expression associated with a desired mood or emotional parameter. | 09-18-2014 |
20140257100 | Porphyrin Microbubbles - The present invention relates to a microbubble comprising a monolayer of porphyrin-phospholipid conjugate, said microbubble having encapsulated therein, and to the use of said microbubble in ultrasound imaging of a target area in a subject. | 09-11-2014 |
20140242095 | ANTIBODIES AND ANTIBODY FRAGMENTS TARGETING SIRP-ALPHA AND THEIR USE IN TREATING HEMATOLOGIC CANCERS - The invention relates to modulating the SIRPα—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRPα antibodies and antibody fragments, preferably used for treating hematological cancer. | 08-28-2014 |
20140221619 | Methods and Compositions for Increasing Protein Production - The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell. ABC50 expression or activity is increased which increases expression of the protein or antibody of interest. The disclosure also provides methods and materials for increasing the sensitivity of a cell to an endoplasmic reticulum stress agent such as Econozole by decreasing the level of ABC50. | 08-07-2014 |
20140194780 | METHOD AND DEVICE FOR APNEA AND HYPOPNEA DETECTION - Disclosed herein is a method and device for apnea and hypopnea detection. In one embodiment, a method is provided for detecting apneas and hypopneas from a digitized breath sound recording acquired from a candidate suspected of sleep apnea. The method comprises scanning an amplitude profile of the digitized breath sound recording to identify a prospect event segment; evaluating characteristics of the prospect event segment for consistency with one or more preset apnea-specific criteria; classifying the prospect event segment as representative of an apnea upon it satisfying each of the one or more apnea-specific criteria; evaluating the prospect event characteristics for consistency with one or more preset hypopnea-specific criteria distinct from the apnea-specific criteria; and classifying the prospect event segment as representative of a hypopnea upon it satisfying each of the one or more hypopnea-specific criteria. | 07-10-2014 |
20140193844 | Biomarkers for Ankylosing Spondylitis - There is described herein methods and peptides for detecting autoantibodies to NOG and/or SOST in a patient sample in order to diagnose of prognosticate Ankylosing Spondylitis in the patient. | 07-10-2014 |
20140193449 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT - Compositions and methods for delivering tumor associated antigens and immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer. | 07-10-2014 |
20140193330 | COMPOSITIONS AND METHODS FOR MULTIMODAL IMAGING - There is provided signal modifying compositions for medical imaging comprising a carrier and signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect of the signal modifying agents that enables prolonged contrast imaging without significant depletion of the signal modifying agent from the carrier. The carriers of the present invention are lipid based or polymer based the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal. | 07-10-2014 |
20140188006 | BREATHING DISORDER IDENTIFICATION, CHARACTERIZATION AND DIAGNOSIS METHODS, DEVICES AND SYSTEMS - Disclosed herein are breathing disorder identification, characterization and diagnosis methods, devices and systems. In general the disclosed methods, devices and systems may rely on the characterization of breath sound amplitudes, periodic breath sounds and/or aperiodic breath sounds to characterize a breathing disorder as obstructive (e.g. obstructive sleep apnea - OSA) or non-obstructive (e.g. central sleep apnea—CSA). | 07-03-2014 |
20140137323 | PATIENT LIFT AND POSITIONING SYSTEM, AND ADJUSTABLE COMPONENTS THEREOF - Described are various embodiments of a patient lift and positioning system, and adjustable components thereof. In one embodiment, a patient positioning interface is suspended from a patient support mechanism and used in positioning a thus supported patient in two or more positions. The interface comprises a legrest portion for supporting a lower body portion of the patient and a backrest portion pivotally coupled to the legrest portion for supporting an upper body portion of the patient. The interface further comprises a powered drive mechanism independently acting on each of the legrest portion and the backrest portion to independently adjust relative to one another a legrest and backrest angle of the legrest portion and backrest portion, respectively. | 05-22-2014 |
20140127763 | Method for the Synthesis of Porphyrin-Phospholipid Conjugates - There is herein described a nanovesicle comprising a bilayer of porphyrin-phospholipid conjugates. Each porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain at one of the sn-1 or the sn-2 positions of one phospholipid. Further, the nanovesicle has a defined regioisomeric ratio of sn-1:sn-2 porphyrin-phospholipid conjugates. | 05-08-2014 |
20140093485 | THYMIDYLATE KINASE FUSIONS AND USES THEREOF - The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer. | 04-03-2014 |
20140086938 | METHODS OF INHIBITING TUMOR GROWTH USING TTK ANTAGONISTS - The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject. | 03-27-2014 |
20140086911 | Methods and Products for Predicting CMTC Class and Prognosis in Breast Cancer Patients - Provided herein are products, uses and method classifying a subject afflicted with breast cancer according to a ClinicoMolecular Triad Classification (CMTC)-1, CMTC-2 or CMTC-3 class. The method involves:
| 03-27-2014 |
20140056904 | Antibodies to TTR and Methods of Use - The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR. | 02-27-2014 |
20140045822 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME - The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: | 02-13-2014 |
20140022283 | AUGMENTED REALITY APPARATUS - Augmented reality apparatus ( | 01-23-2014 |
20130303826 | PROGNOSTIC SIGNATURE FOR ORAL SQUAMOUS CELL CARCINOMA - The present disclosure describes methods and compositions for diagnosing or predicting likelihood of a OSCC recurrence in a subject having undergone OSCC resection comprising: a) determining an expression level of one or more biomarkers selected from Table 4, 5 and/or 7, optionally MMP1, COL4A1, THBS2 and/or P4HA2 in a test sample from the subject, the one or more biomarkers comprising at least one of THBS2 and P4HA2, and b) comparing the expression level of the one or more biomarkers with a control, wherein a difference or a similarity in the expression level of the one or more biomarkers between the test sample and the control is used to diagnose or predict the likelihood of OSCC recurrence in the subject In particular, the present disclosure describes methods and compositions using a four-gene biomarker signature that can predict recurrence of oral squamous cell carcinoma in subjects that have histologically normal surgical resection margins. | 11-14-2013 |
20130289332 | METHODS AND SYSTEMS FOR AUTOMATED PLANNING OF RADIATION THERAPY - Methods and systems for automated treatment planning for radiation therapy are disclosed. Such methods and systems may be useful for treatment planning for intensity-modulate radiotherapy (IMRT). Also provided are user interfaces for automated radiation therapy treatment planning. | 10-31-2013 |
20130261371 | IMAGEABLE ACTIVATABLE AGENT FOR RADIATION THERAPY AND METHOD AND SYSTEM FOR RADIATION THERAPY - Imageable disruptable capsules containing a sensitizing agent or a protecting agent are used to enhance radiation therapy. Said capsules may be imaged by a non-invasive imaging modality, allowing for the determination of the precise timing to disrupt the capsule and release the sensitizing agent or protecting agent using an external energy source. This controlled and timed release of the sensitizing agent or protecting agent provides for enhanced radiation therapy by optimizing the delivery of the sensitizing agent or protecting agent to the target tissues. Systems comprising non-invasive imaging modalities, external energy sources and radiation energy sources are also taught for use with these imageable disruptable capsules. | 10-03-2013 |
20130259858 | Signature for Predicting Clinical Outcome in Human HER2+ Breast Cancer - A method of predicting outcome in a subject with for example Her2+ (ERα | 10-03-2013 |
20130230921 | METHODS FOR ENRICHING PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTE PROGENITOR CELLS AND CARDIOMYOCYTE CELLS BASED ON SIRPA EXPRESSION - The present invention relates to methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on SIRPA expression. | 09-05-2013 |
20130230510 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 09-05-2013 |
20130189253 | MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR - The invention relates to modulating the SIRPα-CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is provided isolated SIRPα and CD47 polypeptides, fragments and fusion proteins for enhancing hematopoietic stem cell engraftment. Further there is provided methods for increasing hematopoietic stem cell engraftment through administration of the above polypeptides. | 07-25-2013 |
20130181046 | APPARATUS, SYSTEM AND METHOD FOR TRACKING DRUGS DURING A REPACKAGING AND ADMINISTERING PROCESS - A system for tracking drugs during a transfer and administering process is configured to reduce labeling errors that can occur during that process. The system includes a storage container reader configured to read a set of one or more storage-container-associated machine-readable indicia positioned on a container containing a drug. The set of one or more storage-container-associated machine-readable indicia identifies the drug. The system further includes, at the point of care of a patient, an indicia-generating device configured to generate machine readable drug-delivery-container-associated indicia identifying the drug based on the storage-container-associated machine-readable indicia. A drug delivery container reader, also located at the point of care, is configured to read both sets of machine readable indicia to verify that the drug delivery container has been correctly labelled. A method implemented by the system results in the reduction in labeling errors. | 07-18-2013 |
20130172772 | MASK AND METHOD FOR USE IN RESPIRATORY MONITORING AND DIAGNOSTICS - Disclosed is a mask for use in respiratory monitoring and/or diagnostics. The mask comprises at least one transducer responsive to sound and/or airflow for generating a signal, and a support structure to rest on the subject's face. In one embodiment, the support structure comprises two or more limbs that provide a transducer support for supporting the transducer at a distance from a nose and mouth area, allowing monitoring via the transducer of sound and/or airflow produced by the subject. Also described is a mask comprising a transducer responsive to airflow for generating a signal and a support structure to rest on the subject's face and extend outwardly over a nose and mouth area to provide a transducer support supporting the transducer at a distance from a nose and mouth area of the subject's face and at a preset orientation, for monitoring via the transducer of airflow produced by the subject. | 07-04-2013 |
20130131088 | TREATING CANCER WITH STATINS AND COMPOUNDS HAVING DIPYRIDAMOLE ACTIVITY - The disclosure pertains to methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a statin in combination with an effective amount of a dipyridamole and/or a compound that has dipyridamole activity. | 05-23-2013 |
20130123273 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR - Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present. | 05-16-2013 |
20130113802 | METHODS AND SYSTEMS FOR VISUALIZATION OF 3D PARAMETRIC DATA DURING 2D IMAGING - Methods and systems for visualization of 3D parametric data in a 2D image. The set of 3D parametric data includes a plurality of voxels in 3D space each associated with at least one parametric value, and the set of 2D image data includes information about a known camera position and a known camera orientation at which the 2D image was obtained. A graphical representation is generated of the parametric values of the voxels corresponding to a viewing surface in 3D space. A virtual 2D view of the viewing surface is determined. The 2D image is displayed registered with the graphical representation of the parametric values of the voxels corresponding to the virtual 2D view. | 05-09-2013 |
20130100268 | EMERGENCY DETECTION AND RESPONSE SYSTEM AND METHOD - Disclosed herein are automated emergency detection and response systems and methods, in accordance with different embodiments of the invention. In some embodiments, a system is provided for detecting and responding to a potential emergency event occurring in respect of a user in or near a designated area. The system comprises one or more sensors disposed in or near the area and a controller operatively coupled to the one or more sensors to receive sensor data therefrom indicative of the user's condition. The controller is further operatively coupled to a designated device in or near the area, operation of the designated device previously identified to effect capture of sensor data. The controller operating on stored statements and instructions to process the sensor data in automatically identifying the event therefrom, communicate a command to the designated device to alter operation thereof based on the previously identified effect so to improve capture of additional sensor data, process the additional sensor data to determine a level of assistance required by the user in response to the event. | 04-25-2013 |
20130096301 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME - The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein. | 04-18-2013 |
20130095487 | Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections - The present invention provides a non-invasive, sensitive, and convenient diagnostic test for persistent Chlamydial infection and diseases arising from persistent Chlamydial infection. The present invention also provides kits for diagnosis of persistent Chlamydial infection. | 04-18-2013 |
20130090712 | FUNCTIONAL ELECTRICAL STIMULATION DEVICE AND SYSTEM, AND USE THEREOF - Disclosed herein is a functional electrical stimulation (FES) device and system. In one embodiment, sequential bipolar pulse stimulation may be provided to an area of a living body via one or more electrode leads applied to the area via a FES device comprising a current pulse generating circuit comprising output nodes for operative coupling to the one or more electrode leads, and configured for operative coupling to a voltage supply. The current pulse generating circuit generally comprises positive and negative stimulation paths drawing from the voltage supply to respectively apply positive and negative currents through the area via the one or more electrode leads. In one example, the stimulation paths comprise respective capacitive elements, a capacitance ratio of which dictating, at least in part, an amplitude ratio of the positive and negative currents, wherein periodic alternative activation of the stimulation paths provides the sequential bipolar pulse stimulation. In another example, each path comprises a respective charging element and a respective activation switch, wherein each respective charging element is charged by the voltage supply and discharged upon activation of the respective activation switch to generate positive and negative current pulses respectively, such that a pulse rise time of the positive and negative current pulses is predominantly dictated by a switching speed of each respective switch. Systems and uses for these devices, and FES in general, are also described. | 04-11-2013 |
20130065789 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosmg, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 03-14-2013 |
20130029873 | METHODS AND COMPOSITIONS FOR DIAGNOSING PULMONARY FIBROSIS SUBTYPES AND ASSESSING THE RISK OF PRIMARY GRAFT DYSFUNCTION AFTER LUNG TRANSPLANTATION - A method for determining pulmonary fibrosis subtype and/or prognosis in a subject having pulmonary fibrosis comprising: a. determining an expression profile by measuring the gene expression levels of a plurality of genes selected from genes listed in Table 1, 2, 3, 4 7, 8, 9, and/or 10, in a sample from the subject; and b. classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts decreased risk of post lung transplant primary graft dysfunction, and wherein a poor prognosis predicts an increased risk of post lung transplant primary graft dysfunction. | 01-31-2013 |
20130006116 | SYSTEM AND METHOD FOR SUB-SURFACE FLUORESCENCE IMAGING - Methods for quantifying fluorescence and optical properties in a turbid medium such as tissue. Devices and systems suitable for the methods are also disclosed. | 01-03-2013 |
20120329761 | USE OF TIGECYCLINE FOR TREATMENT OF CANCER - Cancer stem cells exhibit different metabolic profiles from other cancer cells, such that they do not readily respond to treatment using conventional chemotherapeutic agents. Studies disclosed herein now demonstrate that the glycylcycline antibiotic tigecycline (a tetracycline derivative) exhibits anti-cancer activity, including activity against cancer stem cells. This anti-neoplastic activity appears to be due to inhibition of mitochondrial protein synthesis in the cancer cells. In preferred embodiments, the cancer to be treated is a hematological cancer, such as leukemia, lymphoma or myeloma. | 12-27-2012 |
20120326055 | SYSTEM AND METHOD FOR SUB-SURFACE FLUORESCENCE IMAGING - A system for sub-surface fluorescence imaging is provided, the system comprising: an excitation source for selectably emitting light at at least one of at least two excitation wavelengths or wavelength ranges at a target surface; and a light detector for detecting fluorescence emission wavelengths or wavelength ranges from the target surface; wherein at least one of the at least two excitation wavelengths or wavelength ranges causes fluorescing of at least one marker at a sub-surface depth, the emitted light at each of the at least two excitation wavelengths or wavelength ranges having different depths of optical penetration and causing fluorescing at respective different depths. A method for sub-surface fluorescence imaging is also provided, in some cases exemplified by a reconstruction of the sub-surface fluorescence topography. | 12-27-2012 |
20120296621 | DEVICE AND METHOD FOR PREDICTION OF ACUTE HEART FAILURE MORTALITY - Various embodiments are described herein for a device and a method that can be used to determine a Heart Failure (HF) risk score for an individual with a risk of acute heart failure. The technique comprises employing a HF risk model that uses demographic, transportation, vital signs, blood test, medication and pre-existing co-morbid information to determine the HF risk score for the individual. | 11-22-2012 |
20120288873 | BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME - The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein. | 11-15-2012 |
20120284258 | SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR GENERATING RELEVANT SEARCH RESULTS USING SNOMED CT AND SEMANTIC ONTOLOGICAL TERMINOLOGY - Methods, systems, and computer program products for searching clinical terminology databases, and more specifically systems and methods for searching structured terminology databases that possess structures for terminology synonyms and semantic parent concept relationships—such as the Systematized Nomenclature of Medicine—Clinical Terms (SNOMED CT) data standard—are provided. This involves interfacing with the database using an application program interface to enable communication between the database and a search module, and searching the database using the search module to generate an ordered list of database records by defining a search string, retrieving database records from the database by matching terms associated with concepts in the database to the search string, and retrieving the database records for the concepts associated with the matched terms. The retrieved results can be ordering based upon a relevancy criterion. | 11-08-2012 |
20120259211 | SYSTEMS, DEVICES, AND METHODS EMPLOYING FIBER OPTIC SHAPE TRACKING - The present invention provides systems, devices, and methods employing fiber optic shape and position tracking. The systems, devices, and methods permit measurement of and continuous tracking of the shape and position of objects whose shape dynamically changes with time. Applications include tracking and monitoring of endoscopes for diagnostic and surgical procedures. | 10-11-2012 |
20120253191 | PORPHYRIN NANOVESICLES - The application relates to a nanovesicle comprising a bilayer of at least 15 mol % porphyrin-phospholipid conjugate, wherein the conjugate comprises a porphyrin, porphyrin derivative or porphyrin analog covalently attached to the phospholipid side chain. The nanovesicle can be used for photothermal therapy, photoacoustic imaging, and fluorescence imaging. The application also discloses a method of preparing the said nanovesicle. | 10-04-2012 |
20120251514 | MODULATED PROGRAMMED DEATH LIGAND-1 - The invention provides nucleic acids comprising a nucleotide sequence encoding programmed death ligand-1 (PD-L1) and a nucleotide sequence encoding a fusion protein comprising thymidylate kinase (TMPK) or a variant thereof and a cell surface marker or a variant thereof. Recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and kits relating to the nucleic acids are disclosed. Methods of treating or preventing a disease in a host and methods of suppressing an immune system in a host are also disclosed. | 10-04-2012 |
20120237488 | LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER - A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis. | 09-20-2012 |
20120225954 | METHODS AND COMPOSITIONS FOR THE CLASSIFICATION OF NON-SMALL CELL LUNG CARCINOMA - The disclosure includes a method of screening for, diagnosing or detecting non-small cell lung carcinoma or an increased likelihood of developing non-small cell lung carcinoma in a subject. The method comprises:
| 09-06-2012 |
20120225123 | Use of Synergistic Combinations of an Avermectin and an Antineoplastic Compounds for the Treatment of Hematological Malignancies - The disclosure relates to a method of treating a hematological malignancy comprising administering to a subject in need thereof a synergistic combination of a first compound comprising an effective amount of one or more Avermectins and a second compound comprising a chemotherapeutic, preferably daunorubicin, cyarabine, doxorubicin, idarubicin mitoxantrone, amsacrine, and mixtures thereof. | 09-06-2012 |
20120202840 | Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases - Provided are methods for treating a hematological malignancy comprising administering an effective amount of flubendazole alone or in combination with a vinca alkaloid. Also provided are compositions and kits comprising an effective amount of flubendazole and/or a vinca alkaloid for use in the methods of the disclosure. | 08-09-2012 |
20120189625 | Compositions and Methods for Treating Hematological Cancers Targeting the SIRPA CD47 Interaction - The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia. | 07-26-2012 |
20120155731 | QUANTITATIVE ENDOSCOPY - A method, computer program product and processor for quantitatively registering a 2D endoscopic ROI in a 3D volumetric imaging dataset. An endoscopic dataset and a volumetric imaging are registered to a common coordinate system. A 2D endoscopic ROI is generated within the endoscopic imaging dataset. A 3D surface ROI is generated within the volumetric imaging dataset corresponding to the 2D endoscopic ROI, based on a projection of the 2D endoscopic ROI to the registered common coordinate system. | 06-21-2012 |
20120141603 | METHODS AND COMPOSITIONS FOR LUNG CANCER PROGNOSIS - Disclosed herein are methods and materials for prognosing survival of lung cancer patients, the methods comprising the detection of gains and losses of minimal common regions and/or genes associated with prognosis and benefit of chemotherapy. | 06-07-2012 |
20120128132 | PHANTOM FOR CONTRAST IMAGING CALIBRATION - An imaging phantom for contrast imaging calibration. The phantom includes a body defining at least one cavity having a directional configuration corresponding to at least one pre-determined direction of motion of the phantom. The phantom also includes at least one imaging capsule configured to match and be contained in the at least one cavity. The imaging capsule comprises a material having an imaging contrast different from that of the body. | 05-24-2012 |
20120100999 | PROGNOSTIC GENE EXPRESSION SIGNATURE FOR SQUAMOUS CELL CARCINOMA OF THE LUNG - Provided is a gene expression signature consisting of 12 biomarkers for use in prognosing or classifying a subject with lung squamous cell carcinoma into a poor survival group or a good survival group. The 12-gene signature specific for squamous cell carcinoma consists of the biomarkers RPL22, VEGFA, G0S2, NES, TNFRSF25, DKFZP586P0123, COL8A2, ZNF3, PJPK5, RNFT2, ARHGEF12 and PTPN20A. | 04-26-2012 |
20120094900 | SENSITIZING AGENTS FOR CANCER THERAPY, METHODS OF USE AND METHODS FOR THE IDENTIFICATION THEREOF - There is provided herein methods, compounds and methods for identifying compounds, for sensitizing a subject with cancer to a cancer therapy by inhibiting or down-regulating UROD. | 04-19-2012 |
20120094329 | INCREASING PROTEIN PRODUCTION BY INCREASING ABC50 EXPRESSION OR ACTIVITY - The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell. ABC50 expression or activity is increased which increases expression of the protein or antibody of interest. The disclosure also provides methods and materials for increasing the sensitivity of a cell to an endoplasmic reticulum stress agent such as Econozole by decreasing the level of ABC50. | 04-19-2012 |
20120045419 | METHODS AND USES OF HYPOXIC COMPARTMENT CELLS - The disclosure relates to methods of maintaining and/or expanding an in vitro population of hypoxia compartment cells comprising culturing said population of cells optionally in an oxygen controlled environment, wherein the population of hypoxia compartment cells is exposed to an oxygen concentration of between about 1.5% and about 10%, preferably between about 2% and about 5%, and uses of cells expanded according to these methods. | 02-23-2012 |
20110319427 | USE OF 5AHQ AND BORTEZOMIB FOR THE TREATMENT OF HEMATOLOGICAL DISEASES - The disclosure provides methods and compositions for treating hematological malignancies. In particular, the disclosure provides methods and compositions for treating leukemia, lymphoma and multiple myeloma using bortezomit and 5AHQ (5-ammo-8-hydroxyqumolme) and related compounds that bind non-competitively to an alpha unit of 2OS proteasome and inhibit proteasome activity Kits and commercial packages are also disclosed | 12-29-2011 |
20110280456 | METHOD OF SYNTHETIC IMAGE GENERATION FOR MAGNETIC RESONANCE IMAGING - A method, system and user interface for synthetic image generation for magnetic resonance (MR) imaging is described. A plurality of MR imaging data sets is received, each data set being acquired at a different value for a MR acquisition parameter. A response value for a particular property of tissues is determined, based on a calculated fit of each pixel to a property response model. A synthetic image is generated for a selected value of the MR acquisition parameter, based on the determined response value. An option is provided to dynamically change the selected value of the MR acquisition parameter and the synthetic image is re-generated for the changed value. An option may be provided to dynamically change the value. Another option may be provided to calculate a reliability measure for the synthetic image. | 11-17-2011 |
20110256560 | METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER - Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject. | 10-20-2011 |
20110212176 | CICLOPIROX AND CYTARABINE FOR THE TREATMENT OF LEUKEMIC DISORDERS - The present application relates to compositions and methods for treating leukemic disorders. In particular, the present application relates to compositions and methods for treating the leukemic disorders such as acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) using ciclopirox and cytarabine. | 09-01-2011 |
20110191085 | SYSTEM AND METHOD FOR COMMISSIONING OF A BEAM MODEL FOR A THREE DIMENSIONAL RADIATION THERAPY TREATMENT PLANNING SYSTEM - A system and method for commissioning of a beam model for a three dimensional radiation therapy treatment planning system is described. The system includes an intensity modulated radiotherapy (IMRT) unit for generating a two dimensional intensity modulated beam pattern, a two dimensional diode array for detecting a two dimensional dose map for the beam pattern, and a processor configured to execute instructions for iteratively adjusting one or more parameters for the beam model, in order to increase agreement between the detected dose map and a calculated dose map calculated using the beam model. | 08-04-2011 |
20110151580 | METHOD FOR THE DETECTION OF BREAST CANCER BY DETERMINING ALCAM AND/OR BCAM LEVELS IN A PATIENT - The present application describes biomarkers and methods useful for screening for, diagnosing or detecting the presence and severity of breast cancer in a subject. The present application also provides methods for determining the prognosis of a subject with breast cancer as well as methods for monitoring the therapeutic response to a breast cancer treatment or therapy. | 06-23-2011 |
20110150309 | METHOD AND SYSTEM FOR MANAGING IMAGING DATA, AND ASSOCIATED DEVICES AND COMPOUNDS - Methods, systems, devices and compounds for managing imaging data, such as time series imaging data. The method may include selecting a set of representative voxels from a plurality of voxels in the imaging data, and associating each representative voxel with a voxel database for storing information. For each given voxel in the time series imaging data, at least one corresponding representative voxel may be determined from the set of representative voxels, and information from the given voxel may be aggregated in the voxel database of the determined corresponding representative voxel. | 06-23-2011 |
20110129057 | METHOD FOR DETERMING A CORRECTION FUNCTION FOR CORRECTING COMPUTED TOMOGRAPHIC NUMBERS OF A SMALL TARGET OBJECT IN A CT IMAGE - A method of correcting target region in computed tomographic (CT) image, including the steps of obtaining a CT image of a patient; determining the size of a target object in the CT image; and correcting CT numbers of a portion of the CT image that corresponds to the target object, based on the determined size of the target object. | 06-02-2011 |
20110104130 | THYMIDYLATE KINASE FUSIONS AND USES THEREOF - The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer. | 05-05-2011 |
20110086089 | USE OF P27KIP1 FOR THE PREVENTION AND TREATMENT OF HEART FAILURE | 04-14-2011 |
20110052574 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3Rα; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3Rα (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 03-03-2011 |
20110042580 | FLUORESCENCE QUANTIFICATION AND IMAGE ACQUISITION IN HIGHLY TURBID MEDIA - Various embodiments of methods and systems are described herein for the acquisition and quantification of fluorescence or luminescence signals from a region of interest of an object. The quantification of the acquired signals includes performing at least one ratiometric operation to correct these signals for artifacts due to various factors. | 02-24-2011 |
20110020358 | Methods and Compositions for Detecting Amyotrophic Lateral Sclerosis - The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic lateral sclerosis and kits using the binding proteins of the invention. | 01-27-2011 |
20110015174 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER - A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. | 01-20-2011 |
20100297734 | Fusion Tag Comprising an Affinity Tag and an EF-Hand Motif Containing Polypeptide and Methods of Use Thereof - The application discloses a fusion tag comprising an affinity tag and a polypeptide comprising one or more EF hand motif(s). Preferably, said fusion tag comprises a polyhistidine tag, one or more EF hand motif(s) of calmodulin and a thrombin cleavage site. Methods of using said fusion tag to purify a polypeptide of interest are also disclosed. | 11-25-2010 |
20100291043 | IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia. | 11-18-2010 |
20100288916 | PHANTOMS AND METHODS FOR VERIFICATION IN RADIOTHERAPY SYSTEMS - Methods and phantoms for verification in radiotherapy systems. A phantom for verification in a radiotherapy system may include a body to support a detector surface for obtaining a panoramic image of individual radiation beams in the radiotherapy system. The detector surface may be positioned in an intermediate region between the one or more sources and a target isocenter of the radiotherapy system. The detector surface may at least partially surround the target isocenter. | 11-18-2010 |
20100239578 | MODULATION OF SIRP-ALPHA - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR - The invention relates to modulating the SIRPα-CD47 interaction in order to increase hematopoietic stem cell engraftment and compounds therefor. In some embodiments, there is provided isolated SIRPα and CD47 polypeptides, fragments and fusion proteins for enhancing hematopoietic stem cell engraftment. Further there is provided methods for increasing hematopoietic stem cell engraftment through administration of the above polypeptides. | 09-23-2010 |
20100172838 | ENDOMETRIAL BIOMARKERS - Methods for detecting endometrial diseases or an endometrium phase in a subject are described comprising measuring endometrial markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for endometrial diseases, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for endometrial diseases employing endometrial markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 07-08-2010 |
20100086951 | Pan-Kinase Activation and Evaluation of Signaling Pathways - Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathway signaling protein. The present assay provides a highly sensitive assay that is also useful in patient populations in which obtaining a large cellular sample is difficult, for example, neonates. | 04-08-2010 |
20100056468 | Pyrimidine Derivatives As Anticancer Agents - The present invention includes methods of treating or preventing cancer by administering an effective amount of 6-substituted pyrimidine derivatives of the Formula I to a subject need thereof: | 03-04-2010 |
20100040540 | ANTI CD44 ANTIBODIES FOR ERADICATING LEUKAEMIC STEM CELLS AND BREAST CANCER STEM CELLS - The present invention provides the use of an anti-CD44 antibody, a (Fab′)2, Fab, Fab′ fragment thereof, an IgG or IgM isotype thereof, in a method for eradicating pathological stem cells in cancer therapy, and more specifically in breast cancer and leukaemia therapy. | 02-18-2010 |
20090286854 | APTAMERS DIRECTED TO MUCI - Aptamers against the glycosylated form of MUC1 are described, along with their use in treatment and diagnosis of conditions associated with elevated production of MUC1. | 11-19-2009 |
20090263389 | Use of TGF-Beta Antagonists to Treat or to Prevent Chronic Transplant Rejection - Effective use of a TGF-β antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-β antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-β-mediated fibroproliferation is a characteristic. Expression in situ of a TGF-β antagonist in the form of a recombinant receptor, i.e., TGF-β type III receptor (TGFBIIIR) showed prevention of bronchiolitis obliterans in comparison to untreated controls in a rat lung transplant model. This provides an effective method for preventing or inhibiting chronic rejection of transplant organs such as lung, kidney, liver and heart in vertebrate hosts including human hosts. | 10-22-2009 |
20090028931 | Liposomal compositions for parenteral delivery of agents - The invention provides methods and compositions for loading an agent, such as econazole, onto a liposome for parental delivery. The loading of the agent into a liposome comprises combining the agent with a micelle-forming compound to form a micelle including the agent, where the agent is releasable from the micelle-forming compound, and adding the micelle to the liposome, where the micelle combines with the liposome such that the agent is loaded into the liposome to form a loaded liposome. The methods are suitable for the loading of poorly soluble agents onto liposome. | 01-29-2009 |
20080285913 | Method and apparatus for high resolution coherent optical imaging - A method and an apparatus for examining the sub-surface microstructure of a sample are provided. Radiation from a plurality of optical radiation sources travels along a first optical path. In the first optical path, a device focuses the optical radiation from each of the optical sources into a plurality of respective focal points along the first optical path to provide substantially continuous coverage of a selected portion of the first optical path. Then, a sample on the first optical path within the selected length extending into the sample is scanned along said selected portion of the first optical path. | 11-20-2008 |
20080226554 | Methods For Detecting Markers Associated With Endometrial Disease or Phase - Methods for detecting endometrial diseases or an endometrium phase in a subject are described comprising measuring endometrial markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for endometrial diseases, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for endometrial diseases employing endometrial markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 09-18-2008 |
20080206131 | Compositions and Method for Multimodal Imaging - Provided are signal modifying compositions for medical imaging comprising a carrier and two or more signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect to the signal modifying agents, which enables prolonged contrast imaging without significant depletion of the signal modifying agents from the carrier. The carriers of the present invention are lipid based or polymer based, the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal. | 08-28-2008 |